title: PK-PD modelling of the effect of cefaclor on four different bacterial strains.
abstract: The effect of cefaclor against relevant bacterial strains was studied by employing a combined in vivo pharmacokinetic (PK)-in vitro pharmacodynamic (PD) approach. For this purpose selected isolates of Escherichia coli, Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae were exposed in vitro to the interstitial cefaclor profile obtained in vivo in the interstitial space fluid of human tissue after administration of commonly used doses of cefaclor and the change in the number of colony forming units per millilitre (CFU/ml) versus time was monitored. Fitting of the data using a modified E(max)-model resulted in a set of mean pharmacodynamic parameters (k0, k(max), EC50) for each bacterial strain. The parameters derived from these experiments were used in a computer-simulation of the antibacterial effects for different dosing regimens and formulations of cefaclor, notably an immediate (IR) and a modified (MR) release formulation. Dosage regimens were compared using the ratio between the number of bacteria remaining after 24 h of a given treatment (N24h). The results indicate that the number of bacteria of all investigated strains killed per day is equivalent when the same daily dose is administered twice a day with the MR dosage form than when given three times a day with the IR dosage form, in spite of the fact that the MR dosage form has approximately 20% lower bioavailability. Best results were obtained with the three-times a day regimen of the MR formulation. In conclusion, the present in vivo-PK/in vitro-PD simulations of the antimicrobial effects of cefaclor indicate that a twice-daily treatment with a MR formulation may offer a convenient and safe alternative to the conventional tid treatment.
authors.affiliation: Department of Pharmaceutics, College of Pharmacy, University of Florida, PO Box 100494, Gainesville, FL 32610-0494, USA.
authors.forename: Amparo
authors.initials: A
authors.lastname: de la Peña
authors.forename: Annemarie
authors.initials: A
authors.lastname: Gräbe
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Rand
authors.forename: Edelgard
authors.initials: E
authors.lastname: Rehak
authors.forename: Jens
authors.initials: J
authors.lastname: Gross
authors.forename: Ursula
authors.initials: U
authors.lastname: Thyroff-Friesinger
authors.forename: Markus
authors.initials: M
authors.lastname: Müller
authors.forename: Hartmut
authors.initials: H
authors.lastname: Derendorf
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development; D001424:Bacterial Infections / Q000188:drug therapy; D002433:Cefaclor / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D003470:Culture Media; D004355:Drug Stability; D004926:Escherichia coli / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D001936:Moraxella catarrhalis / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D003470:Culture Media; D002433:Cefaclor